As part of our ongoing aim to bring you reports of new developments, we have added a review which summarises the outcomes of three recent studies that evaluated data obtained from a large US healthcare database to determine the impact of remdesivir treatment of hospitalised patients with COVID-19 in the late Omicron era.
Independent commentary for the review has been provided by Professor Paul Griffin, Infectious Diseases Physician and Clinical Microbiologist, Director of Infectious Diseases at Mater Health Services and Head of the Mater Clinical Unit, University of Queensland School of Medicine.
Please login below to download this issue (PDF)